HilleVax Stock (NASDAQ:HLVX)
Previous Close
$1.87
52W Range
$1.55 - $20.22
50D Avg
$1.81
200D Avg
$9.34
Market Cap
$94.59M
Avg Vol (3M)
$287.65K
Beta
0.80
Div Yield
-
HLVX Company Profile
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
HLVX Performance
Peer Comparison
Ticker | Company |
---|---|
VIGL | Vigil Neuroscience, Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
CGEM | Cullinan Oncology, Inc. |
CNTA | Centessa Pharmaceuticals plc |
MLYS | Mineralys Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
IPSC | Century Therapeutics, Inc. |
STRO | Sutro Biopharma, Inc. |
CSBR | Champions Oncology, Inc. |
TRDA | Entrada Therapeutics, Inc. |
CCCC | C4 Therapeutics, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
MNOV | MediciNova, Inc. |
PHVS | Pharvaris N.V. |
PEPG | PepGen Inc. |
MOLN | Molecular Partners AG |
PRDS | Pardes Biosciences, Inc. |
OPT | Opthea Limited |
STTK | Shattuck Labs, Inc. |
ELYM | Eliem Therapeutics, Inc. |